Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Lajos Géczi et al.|The Lancet Oncology|2021Cited by 645
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N., Celio Kussumoto, Dana E. Rathkopf et al.|Journal of Clinical Oncology|2023Cited by 317